

Clinical Experience with the NeVa thrombectomy device


SOUROUR, SHOTAR, CLARENCON
HOPITAUX UNIVERSITAIRES PARIS - PITIÉ SALPÊTRIÈRE CHARLES FOIX

Single site experience: retrospective analysis of 15 patients with LVOs in the MCA-ACA territory treated with the NeVa™ device.

Baseline Information – 14 Patients

| | |
|---|----------------|
| Age*: | Mean: 65 |
| | Range: 47 – 84 |
| Gender: | 40 % Male |
| NIHSS at admission*: | Mean: 18 |
| | Range: 2-38 |
| **info missing for 1 patient, GCS score 8 | |
| IV-tPA given to: | 47 % |

Occlusion Sites



Recanalization Scores with NeVa where it was used as 1st line treatment (n = 11)

| | | |
|--|-------|------------|
| TICI 3 | 7/11 | 64% |
| TICI 2C+ | 8/11 | 73% |
| TICI 2B+ | 10/11 | 91% |
| Mean number of passes to achieve final score: 1.3 | | |

Recanalization Scores of all cases, including where it was used as rescue treatment (n=15)


| | | |
|--|-------|------------|
| TICI 3 | 11/15 | 73% |
| TICI 2C+ | 12/15 | 80% |
| TICI 2B+ | 14/15 | 93% |
| <i>In 1 case: TICI 2C en M2/TICI 3 en ACA (counted as TICI 2C in totals)</i> | | |

Patient Outcomes

NIHSS

- Final mean NIHSS assessment was **7.8** (Range 0-29) data available for 13 of 15 patients
- Improvement versus pre-treatment mean NIHSS: **10.4**

mRS



Conclusion

Our initial 15 patients with NeVa confirm the FIM results. We recommend a larger, multi-center study to confirm the trend.